Skip to main content

Ametropia

3
Pipeline Programs
5
Companies
12
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
0
2
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Alcon
AlconFORT WORTH, TX
2 programs
2
TOTAL30Phase 44 trials
soft contact lensPhase 41 trial
Active Trials
NCT06967298Completed60Est. Nov 2024
NCT06266728Completed48Est. Aug 2024
NCT06052046Completed48Est. Jun 2024
+2 more trials
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
Carboxymethylcellulose sodium and GlycerinPhase 2/31 trial
Active Trials
NCT00691197Completed246Est. Oct 2008
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
3 programs
Purevision Lenses with ReNu MultiplusN/A1 trial
SUPRACOR RegularN/A1 trial
Transepithelial Photorefractive keratectomyN/A1 trial
Active Trials
NCT00722891Completed30Est. Sep 2009
NCT04617080Completed60Est. Feb 2024
NCT04698174Completed39Est. Mar 2022
Bausch + Lomb
Bausch + LombNJ - Bridgewater
3 programs
Purevision Lenses with ReNu MultiplusN/A
SUPRACORPhase N/A
Transepithelial Photorefractive KeratectomyPhase N/A
Johnson & Johnson
Johnson & JohnsonNEW BRUNSWICK, NJ
3 programs
alphafilcon A toricN/A1 trial
senofilcon A contact lensesN/A1 trial
senofilcon A toricN/A1 trial
Active Trials
NCT00630305Completed37Est. Jul 2008
NCT03319212Completed105Est. Aug 2018
NCT00639379Completed89Est. Jun 2008

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Alconsoft contact lens
AbbVieCarboxymethylcellulose sodium and Glycerin
AlconTOTAL30
AlconTOTAL30
AlconTOTAL30
AlconTOTAL30
Bausch HealthTransepithelial Photorefractive keratectomy
Bausch HealthSUPRACOR Regular
Johnson & Johnsonsenofilcon A contact lenses
Bausch HealthPurevision Lenses with ReNu Multiplus
Johnson & Johnsonsenofilcon A toric
Johnson & Johnsonalphafilcon A toric

Clinical Trials (12)

Total enrollment: 865 patients across 12 trials

NCT00349063Alconsoft contact lens

Contact Lens Wettability

Start: Jul 200555 patients
Phase 4Completed
NCT00691197AbbVieCarboxymethylcellulose sodium and Glycerin

Safety and Acceptability of Using a Rewetting Drop With Contact Lens Wear

Start: Mar 2008Est. completion: Oct 2008246 patients
Phase 2/3Completed

Total30 For Contact Lens Dropouts

Start: Apr 2024Est. completion: Nov 202460 patients
N/ACompleted

T30 for Astigmatism in Digital Device Users

Start: Mar 2024Est. completion: Aug 202448 patients
N/ACompleted

Total30 for Astigmatism Contact Lenses

Start: Oct 2023Est. completion: Jun 202448 patients
N/ACompleted

Total30 Sphere Contact Lenses

Start: Jan 2022Est. completion: Jul 202248 patients
N/ACompleted
NCT04698174Bausch HealthTransepithelial Photorefractive keratectomy

Safety and Efficacy of a New Transepithelial Photorefractive Keratectomy Treatment

Start: Feb 2021Est. completion: Mar 202239 patients
N/ACompleted
NCT04617080Bausch HealthSUPRACOR Regular

Safety and Efficacy of Different Add Powers With a New Presbyopic Lasik Treatment Algorithm

Start: Jan 2020Est. completion: Feb 202460 patients
N/ACompleted
NCT03319212Johnson & Johnsonsenofilcon A contact lenses

Clinical Characterization of Symptomatic Populations

Start: Sep 2017Est. completion: Aug 2018105 patients
N/ACompleted
NCT00722891Bausch HealthPurevision Lenses with ReNu Multiplus

Ocular Responses to Short and Long-term Lens Wear

Start: Jul 2008Est. completion: Sep 200930 patients
N/ACompleted

Comparison of Two Toric Contact Lenses on Current Toric Wearers

Start: Feb 2008Est. completion: Jun 200889 patients
N/ACompleted
NCT00630305Johnson & Johnsonalphafilcon A toric

Endothelial Bleb Response With Toric Lenses

Start: Jan 2008Est. completion: Jul 200837 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.